MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes
- 1 January 2006
- journal article
- research article
- Published by Elsevier in Experimental Hematology
- Vol. 34 (1) , 44-53
- https://doi.org/10.1016/j.exphem.2005.09.016
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytesBlood, 2005
- Induction of Unresponsiveness Limits Tumor Protection by Adoptively Transferred MDM2-Specific Cytotoxic T LymphocytesCancer Research, 2004
- Identification of Epstein-Barr Virus (EBV) Nuclear Antigen 2 (EBNA2) Target Proteins by Proteome Analysis: Activation of EBNA2 in Conditionally Immortalized B Cells Reflects Early Events after Infection of Primary B Cells by EBVJournal of Virology, 2004
- A HLA‐A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitopeInternational Journal of Cancer, 2002
- MDM2: life without p53Trends in Genetics, 2001
- MDM2 — master regulator of the p53 tumor suppressor proteinGene, 2000
- CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.Journal of Clinical Investigation, 1997
- Analysis of the p53 and MDM‐2 gene in acute myeloid leukemiaEuropean Journal of Haematology, 1996
- A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3European Journal of Immunology, 1994
- Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomasCancer Letters, 1994